Overview

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Status:
RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
Phase:
PHASE1
Details
Lead Sponsor:
St Vincent's Hospital, Sydney